Bernadette Redd
Overview
Explore the profile of Bernadette Redd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Myojin Y, Babaei S, Trehan R, Hoffman C, Kedei N, Ruf B, et al.
Gut
. 2025 Feb;
PMID: 39965889
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. The combination of tremelimumab and durvalumab is now a standard treatment option for advanced HCC. Objective: To study immune...
2.
Turriff A, Annunziata C, Malayeri A, Redd B, Pavelova M, Goldlust I, et al.
N Engl J Med
. 2025 Jan;
391(22):2123-2132.
PMID: 39774314
Background: Cell-free DNA (cfDNA) sequence analysis to screen for fetal aneuploidy can incidentally detect maternal cancer. Additional data are needed to identify DNA-sequencing patterns and other biomarkers that can identify...
3.
Panebianco V, Briganti A, Efstathiou J, Galgano S, Luk L, Muglia V, et al.
Eur Urol
. 2024 Sep;
86(6):485-487.
PMID: 39317635
The American College of Radiology Vesical Imaging-Reporting and Data System (VI-RADS) Steering Committee will strive to ensure high-quality imaging practices for bladder cancer (BC) and improve outcomes for BC patients....
4.
Apolo A, Girardi D, Niglio S, Nadal R, Kydd A, Simon N, et al.
J Clin Oncol
. 2024 Jul;
42(25):3033-3046.
PMID: 38954785
Purpose: Cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) have shown promising efficacy and safety in patients with metastatic urothelial carcinoma (mUC), metastatic renal cell carcinoma (mRCC), and rare...
5.
Mironova M, Gopalakrishna H, Viana Rodriguez G, Majeed N, Hitawala A, Fuss I, et al.
Aliment Pharmacol Ther
. 2024 Apr;
59(12):1527-1538.
PMID: 38629442
Background: Non-cirrhotic portal hypertension (NCPH) is a spectrum of liver diseases, including porto-sinusoidal vascular disorder, with portal hypertension (PH) in the absence of cirrhosis. The natural history and diagnostic approach...
6.
Panwar J, Tolend M, Kirkhus E, Meyers A, Redd B, Sudol-Szopinska I, et al.
Semin Arthritis Rheum
. 2024 Apr;
66:152437.
PMID: 38564998
Inter-reader reliability of a new scoring system for evaluating joint inflammation and enthesitis in whole body MRI (WBMRI) in juvenile idiopathic arthritis was tested. The scoring system grades 732 item-region...
7.
Giudice E, Huang T, Nair J, Zurcher G, McCoy A, Nousome D, et al.
Nat Commun
. 2024 Mar;
15(1):2805.
PMID: 38555285
The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we report the...
8.
Monge C, Xie C, Myojin Y, Coffman-DAnnibale K, Hrones D, Brar G, et al.
Cancer Med
. 2024 Jan;
13(3):e6912.
PMID: 38205877
Background: Current standard of care for advanced biliary tract cancer (BTC) is gemcitabine, cisplatin plus anti-PD1/PD-L1, but response rates are modest. The purpose of this study was to explore the...
9.
Coffman-DAnnibale K, Myojin Y, Monge C, Xie C, Hrones D, Wood B, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38184304
Background: Microsatellite stable colorectal liver metastases (MSS CLM) maintain an immunosuppressive tumor microenvironment (TME). Historically, immune-based approaches have been ineffective. VB-111 (ofranergene obadenovec) is a genetically-modified adenoviral vector targeting the...
10.
Gamble L, McClelland P, Teke M, Samaranayake S, Juneau P, Famiglietti A, et al.
NPJ Breast Cancer
. 2023 Oct;
9(1):87.
PMID: 37872305
No abstract available.